210 related articles for article (PubMed ID: 30593771)
1. PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.
Mengel D; Hong W; Corbett GT; Liu W; DeSousa A; Solforosi L; Fang C; Frosch MP; Collinge J; Harris DA; Walsh DM
Brain Res; 2019 May; 1710():125-135. PubMed ID: 30593771
[TBL] [Abstract][Full Text] [Related]
2. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
3. Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain.
Hong W; Wang Z; Liu W; O'Malley TT; Jin M; Willem M; Haass C; Frosch MP; Walsh DM
Acta Neuropathol; 2018 Jul; 136(1):19-40. PubMed ID: 29687257
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
5. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
6. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
[TBL] [Abstract][Full Text] [Related]
7. Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.
Kong C; Xie H; Gao Z; Shao M; Li H; Shi R; Cai L; Gao S; Sun T; Li C
Virol Sin; 2019 Oct; 34(5):475-488. PubMed ID: 31093882
[TBL] [Abstract][Full Text] [Related]
8. Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a
Younan ND; Chen KF; Rose RS; Crowther DC; Viles JH
J Biol Chem; 2018 Aug; 293(34):13090-13099. PubMed ID: 29887525
[TBL] [Abstract][Full Text] [Related]
9. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.
Ferrera D; Mazzaro N; Canale C; Gasparini L
Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120
[TBL] [Abstract][Full Text] [Related]
10. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.
Rösener NS; Gremer L; Reinartz E; König A; Brener O; Heise H; Hoyer W; Neudecker P; Willbold D
J Biol Chem; 2018 Oct; 293(41):15748-15764. PubMed ID: 30131337
[TBL] [Abstract][Full Text] [Related]
11. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
13. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.
Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683
[TBL] [Abstract][Full Text] [Related]
14. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
[TBL] [Abstract][Full Text] [Related]
15. Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
König AS; Rösener NS; Gremer L; Tusche M; Flender D; Reinartz E; Hoyer W; Neudecker P; Willbold D; Heise H
J Biol Chem; 2021; 296():100499. PubMed ID: 33667547
[TBL] [Abstract][Full Text] [Related]
16. Extracellular Protein Aggregates Colocalization and Neuronal Dystrophy in Comorbid Alzheimer's and Creutzfeldt-Jakob Disease: A Micromorphological Pilot Study on 20 Brains.
Jankovska N; Olejar T; Matej R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672582
[TBL] [Abstract][Full Text] [Related]
17. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
[TBL] [Abstract][Full Text] [Related]
18. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.
Whitehouse IJ; Miners JS; Glennon EB; Kehoe PG; Love S; Kellett KA; Hooper NM
PLoS One; 2013; 8(4):e59554. PubMed ID: 23577068
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-β oligomers in cellular models of Alzheimer's disease.
Fontana IC; Zimmer AR; Rocha AS; Gosmann G; Souza DO; Lourenco MV; Ferreira ST; Zimmer ER
J Neurochem; 2020 Nov; 155(4):348-369. PubMed ID: 32320074
[TBL] [Abstract][Full Text] [Related]
20. Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.
Wang Z; Jackson RJ; Hong W; Taylor WM; Corbett GT; Moreno A; Liu W; Li S; Frosch MP; Slutsky I; Young-Pearse TL; Spires-Jones TL; Walsh DM
J Neurosci; 2017 Dec; 37(49):11947-11966. PubMed ID: 29101243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
